Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members have more privileges) LoginRegister
Psoriasis Club is a friendly on-line Forum where people with psoriasis or psoriatic arthritis
can get together and share information, get the latest news, or just chill out with others who understand. It is totally
self funded and we don't rely on drug manufacturers or donations. We are proactive against Spammers,
Trolls, And Cyberbulying and offer a safe friendly atmosphere for our members.
So Who Joins Psoriasis Club?
We have members who have had psoriasis for years and some that are newly diagnosed. Family and friends of those with psoriasis
are also made welcome. You will find some using prescribed treatments and some using the natural approach. There are people who
join but keep a low profile, there are people who just like to help others, and there are some who just like
to escape in the Off Topic Section.
Joining Couldn't Be Easier: If you are a genuine person who would like to meet others who understand,
just hit the Register button and follow the instructions.
Members get more boards and privileges that are not available to guests.
OK So What Is Psoriasis?
Psoriasis is a chronic, autoimmune disease that appears on the skin. It
occurs when the immune system sends out faulty signals that speed up the
growth cycle of skin cells. Psoriasis is not contagious. It commonly
causes red, scaly patches to appear on the skin, although some patients
have no dermatological symptoms. The scaly patches commonly caused by
psoriasis, called psoriatic plaques, are areas of inflammation and
excessive skin production. Skin rapidly accumulates at these sites which
gives it a silvery-white appearance. Plaques frequently occur on the
skin of the elbows and knees, but can affect any area including the
scalp, palms of hands and soles of feet, and genitals. In contrast to
eczema, psoriasis is more likely to be found on the outer side of the
joint.
The disorder is a chronic recurring condition that varies in severity
from minor localized patches to complete body coverage. Fingernails and
toenails are frequently affected (psoriatic nail dystrophy) and can be
seen as an isolated symptom. Psoriasis can also cause inflammation of
the joints, which is known as (psoriatic arthritis). Ten to fifteen
percent of people with psoriasis have psoriatic arthritis.
The cause of psoriasis is not fully understood, but it is believed to
have a genetic component and local psoriatic changes can be triggered by
an injury to the skin known as Koebner phenomenon. Various
environmental factors have been suggested as aggravating to psoriasis
including stress, withdrawal of systemic corticosteroid, excessive
alcohol consumption, and smoking but few have shown statistical
significance. There are many treatments available, but because of its
chronic recurrent nature psoriasis is a challenge to treat. You can find more information
Here!
Got It, So What's The Cure?
Wait Let me stop you there! I'm sorry but there is no cure. There are things that can help you
cope with it but for a cure, you will not find one.
You will always be looking for one, and that is part of the problem with psoriasis There are people who know you will be
desperate to find a cure, and they will tell you exactly what you want to hear in order to get your money. If there is a
cure then a genuine person who has ever suffered with psoriasis would give you the information for free. Most so called cures
are nothing more than a diet and lifestyle change or a very expensive moisturiser. Check out the threads in
Natural Treatments first and save your money.
Great so now what? It's not all bad news, come and join others at Psoriasis Club and talk about it. The best help is from accepting it and talking
with others who understand what you're going through. ask questions read through the threads on here and start claiming
your life back. You should also get yourself an appointment with a dermatologist who will help you find something that can
help you cope with it. What works for some may not work for others
Posted by: Kat - Sat-30-08-2014, 14:20 PM
- Replies (2)
The first time I went to the dermatologist, he prescribed fluocinolone acetonide and told me it "should" come with a shower cap, to wear it overnight. Well, what I got from the pharmacist was fluocinolone acetonide BODY oil, no shower cap. Plus the derm told me to use on all spots so it seemed right. I didn't think anything of it other than perhaps they no longer put the shower cap with it. I used it and it did help soothe, but didn't help a lot with itchiness, it didn't clear up anthing however so next visit he put me on meds as mentioned in other posts.
Anyway, I told him I was low on the oil so he gave me another prescription for the same thing. THIS time, the pharmacy gave me fluocinolone acetonide SCALP oil. (I'm thinking it was what he prescribed the first time and the pharmacy just got it wrong.) It appears to be pretty much the same thing but the scalp oil is a little thicker (I think) and it did come with a shower cap.
I ran out of the first bottle (the body oil, although I didn't realize at this time there was a difference) and opened the second one. When I saw the shower cap, I thought they had just left it out of the first one but I looked and saw the first one said BODY oil and the second specifically said SCALP oil. So anyway I used the scalp oil for the first time this last Thursday (I was told not to use topicals on days of light therapy)
Anyway, it helped a lot! I moistened my scalp, applied the oil, put on the shower cap (wouldn't win any fashion awards for that one!) and left it on for 4 hours. No way can I sleep with it as I'm too restless and that cap would be off within half and hour. Wearing the cap really helped with keeping the moisture in and after washing out the oil, I gently ran a comb along the scalp and descaled. The scales were rolling off practically. I didn't force it as didn't want to irritate my scalp and make it sore. For the first time in a LONG time, my scalp was barely itchy at all. I had light therapy yesterday and today my skin is "tightening" up and I can feel the dry scales. I plan on using this a couple of times a week on days I don't have light therapy and hope it continues to relieve some of the itching.
I wanted to mention this as anyone suffering from scalp psoriasis and severe itching might want to ask their dermatologist if this would be something they could try. Just make sure you ask about the SCALP oil.
Posted by: Fred - Fri-29-08-2014, 20:38 PM
- Replies (4)
The FDA (U.S. Food and Drug Administration) says “Psoriasis has a great emotional impact on some patients. But it doesn’t have to, given the right care and treatment.”
Quote:
The more scientists learn about psoriasis, the more therapeutic options are becoming available for patients with this skin disease.
“As we better understand the disease, researchers know more about what specific factors to target in order to develop effective treatments,” says Melinda L. McCord, M.D., a dermatologist at the Food and Drug Administration.
The treatment for psoriasis has changed from the previous gradual step-by-step approach. Today, doctors seek to optimize treatment from the first visit—whether with phototherapy or systemic therapies—based on the specific needs of each patient.
“Tomorrow’s treatments will become even more personalized because the drugs in development now are targeting different aspects of the immune system,” McCord notes.
Psoriasis is an immune system disorder characterized by inflammation and the rapid overproduction of skin cells, creating scaling, pain, swelling, heat and redness. About 7.5 million Americans have psoriasis, a skin condition that can create significant physical and emotional discomfort.
Therapies for psoriasis include:
Medicines applied to the skin (topical treatment)
Light treatment (phototherapy)
Drugs taken by mouth or injection (systemic therapy)
There is no cure for psoriasis, so the main goals of treatment are to reduce inflammation and to stop the skin cells from growing so quickly.
In the past, doctors treated psoriasis using a “step-wise approach.” Patients with mild to moderate psoriasis would start with topical therapies and, if they did not respond well to that, move on to other treatments, such as systemic therapy or phototherapy. This approach called for treating people with moderate to severe psoriasis with phototherapy or traditional systemic therapies—drugs such as methotrexate and cyclosporine—before offering them biologic therapies (a type of treatment that works with your immune system).
That strategy has changed to a more patient-specific approach. Today, patients and their doctors can choose a treatment based on its effectiveness, the severity of their disease, lifestyle considerations, risk factors, and associated diseases (co-morbidities).
The most recent biologic product approved by the FDA for the treatment of psoriasis is Stelara (ustekinumab). Ustekinumab contains an antibody that’s produced in a laboratory and designed to bind to a specific target in the immune system. “When given to patients, this antibody blocks the action of two proteins (interleukin 12 and 23) that contribute to the inflammation and the overproduction of skin cells. By targeting these proteins, ustekinumab can interrupt the inflammatory pathway,” McCord says.
“Looking forward, the drugs in development are targeting different pathways in the immune system that lead to inflammation. Researchers are exploring the importance of interleukin 17,” McCord says. “They’re also looking at proteins and molecules that can interrupt cellular signaling, which can increase the spreading of the inflammation.”
“As we learn more about the immune pathways that lead to the development of psoriasis, we can target specific molecules for treatment and make more therapeutic options available to patients,” McCord says. “Understanding the disease gives us the opportunity to target specific factors.”
McCord recommends a team approach to treating psoriasis. Patients, families and their health care providers need to work together to address the multiple diseases that may occur in association with psoriasis, including the risk of developing metabolic syndrome (the occurrence of obesity, high blood pressure, high cholesterol and diabetes in one patient), lymphoma, heart disease and/or depression. “We do not completely understand the relationship of these co-morbidities to psoriasis, but it is an area of active research,” she adds.
Because psoriasis is a chronic disease with no cure, patients may need to use treatments for a long time. Many therapies approved by FDA have been evaluated for extended time periods.
Psoriasis has environmental and genetic components. It is more common in adults and can run in families. What triggers it? A virus? Bacteria? Stress? Other environmental factors? “We just don’t know,” McCord says.
The good news is that patients can treat some of the signs and symptoms of psoriasis with simple measures. For example, regular use of moisturizers may improve the itching and scaling. Reducing or limiting tobacco use and alcohol consumption may decrease the number of flares of psoriasis. Lifestyle changes—such as maintaining a healthy weight and being physically active—may help lessen or prevent the development of associated diseases.
McCord advises patients to seek treatment early from a doctor experienced with the disease. A dermatologist can provide patients with the correct diagnosis and information to manage the disease. “If you are diagnosed and treated early, you may avoid the pitfalls of ineffective and inappropriate therapy,” she adds.
Some patients become easily discouraged about treatments, but newer therapies may make them more comfortable. That’s why McCord says patients should investigate treatment options early and educate themselves about their condition. Even if patients have a mild case of psoriasis and decide they don’t want a particular treatment option, there are ways they can decrease their symptoms.
“Psoriasis has a great emotional impact on some patients. But it doesn’t have to, given the right care and treatment,” she says.
Posted by: Fred - Thu-28-08-2014, 20:29 PM
- Replies (30)
After reading a conversation here: RE: Hey fellow sufferers I thought it would be interesting to start a new poll.
Question: Do you think there will ever be a cure for psoriasis? (I'm talking cure as in it's gone from the whole world and will never come back as that is a cure to me)
You can vote in the poll above (open to guests too) Members can also add comments in this thread.
Hey everyone new to this forum but not in regards to P.
I thought I would share my experience with you after starting Acitretin Aug 2014.
Suffered since age 12 and as a veteran of the vast array of meds on offer I am now at the stage of trying Acitretin. My P by the way is on the high end of moderate bordering on severe. Apparently, after bloods, cholestorol etc I am an ideal candidate. This is my second attempt at an oral drug as I reacted adversely to ciclosporin. I will share with you any side effects and effects on skin.
Day 1: 35mg Acitretin taken after breakfast, started to develop a pressure headache, foggy feeling and this didn't stop only respite is when asleep, nightmare.
Day 2: Same strict routine and again now a hazy headache not very alert, with a foggy feeling, after a nap feel brighter continued throughout day again nightmare.
Day 3: Headaches don't seem to be there today no pain and it seems the fogginess is going feel more brighter than last two days. Not sure whether related but my IBS flared badly in the am.
No significant change in skin or anything else will try and update again further along. However, I live in hope this treatment may help me but don't hold out much optimism considering years trying other treatments that have failed, anyway we will see.
Ok folks after a really bad flare over the last few weeks, I've decided to forego the natural remedy route for now and give the Acitrecin and topical steroids a try. I found a nifty back applicator at the pharmacy so I can apply the steroid cream all over. Oh I'm just going to lube myself up and have a party! I'm going to be diligent about sticking with the routine and see if there is any progress in a month when I go back to the Derm. I'm hoping I will tolerate the Acitrecin as I cannot go on biologics because of my cancer history. My Dr. did tell me I could go on methotrexate and wanted to put me on that because he said it would work faster than the Acitrecin but my cancer Dr. says it's poison and to stay away. I know many here have had good luck with Methotrexate and if Acitrecin doesn't work, I'll have to give it a try. Dr. thinks I have about 70% coverage btwn my scalp, face, torso, arms and legs and said he rarely has seen a case spread so fast and be so acute. Lucky me. Also taking Atarax for the itch. I wish I didn't have to deal with any of this and it would just go away on it's own but I know that's not going to happen.
I'll post on the natural remedies board about my experience with Functional Medicine Dr. I had last week.
Posted by: Fred - Mon-25-08-2014, 19:18 PM
- Replies (1)
Following on from this thread Covagen Initiates Phase Ib/IIa Study with COVA322 Janssen today announced it has now acquired Covagen. As for if this is a good thing or a bad thing we will have to wait and see.
Quote:
Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired Covagen AG, a privately-held, biopharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform. The opportunity was identified and facilitated through the Johnson & Johnson Innovation Center in London. The company's lead product, COVA 322, a bispecific anti-tumor necrosis factor (TNF)-alpha/anti-interleukin (IL)-17A FynomAb, is in Phase 1b study for psoriasis and holds potential as a treatment for a broad range of inflammatory diseases including rheumatoid arthritis. Covagen develops FynomAbs, multi-specific protein therapeutics, by fusing its fully human Fynomer binding proteins to antibodies. Fynomers are small binding proteins engineered to bind to target molecules with the same affinity and specificity as antibodies. The tailored architecture and novel mode of action of FynomAb therapeutics may offer enhanced efficacy in the treatment of a broad range of inflammatory diseases and other conditions. Financial terms of the transaction have not been disclosed.
"Our goal is to translate advancements in immunology science into next-generation therapies that improve patient outcomes," said Susan B. Dillon, Ph.D., Global Therapeutic Area Head, Immunology, Janssen Research & Development, LLC. "Our interest in Covagen stems from the company's scientific acumen, their novel FynomAb platform, and the potential of COVA 322, a bispecific designed to achieve better control of inflammation by blocking two key cytokines that have been implicated in disease pathogenesis and progression. We look forward to progressing COVA 322 development, and to further expanding the potential of multispecific biologics for immunologic and other diseases. This exciting opportunity underscores the value of co-locating scientific innovation leads at our regional hubs in thriving life science communities as part of our strategy to identify and realize new opportunities and build long-term competitive advantage."
Covagen will maintain a research presence in Zurich-Schlieren, Switzerland, and will continue to focus on the further development and application of the Fynomer technology. "We are very excited to further develop our pipeline and innovative FynomAb platform as part of Janssen," said Julian Bertschinger, Ph.D., co-founder and former CEO of Covagen. "Janssen's tremendous knowledge in the research and development of biologics provides us with a great environment to develop novel FynomAb-based therapeutics addressing unmet medical needs."
Covagen was co-founded in 2007 by Julian Bertschinger, Ph.D., and Dragan Grabulovski, Ph.D. as a spin-off company of ETH Zurich, Switzerland.
Source: investor.jnj.com
What do you think?
Is it good for a big company with loads of shareholders taking over a private company?
Posted by: Jen - Mon-25-08-2014, 17:43 PM
- Replies (5)
Hi I've just joined and wondered if I could pick someone's brains? I've had p for 10 years I've got plaque p 90% covered and nail p I'm not sure how to work out my p score? I'm using dovobet and it's great at clearing it but the minute I stop using it I'm covered again and worse! I've been trying to decide weather to go to tablet treatment but they worry me. I've been offered methotrexate but I'm unsure. I have bowel stomach trouble also so I'm unsure if I'd be prescribed the fumaderm? One more thing (sorry) I think I may have psoriatic arthritis just wondering how you find out if you do? Thankyou and hope someone can advise me on some new treatment x
Posted by: Fred - Fri-22-08-2014, 10:03 AM
- Replies (4)
Eli Lilly have released their phase 3 data for Ixekizumab and stating it is statistically superior to Enbrel (etanercept) and placebo on all skin clearance measures.
Quote:Study design:
In the three UNCOVER studies, patients were assigned to receive either placebo or ixekizumab (80 mg every two or four weeks) for 12 weeks, following a 160 mg starting dose. In the two active comparator studies (UNCOVER-2 and 3), patients could be assigned to receive etanercept 50 mg twice weekly for 12 weeks. In UNCOVER-1, responders to treatment were assigned to continue treatment on either placebo or ixekizumab (80 mg every 4 or 12 weeks) for up to 60 weeks.
Results:
Patients treated with both dosing regimens of ixekizumab had significantly greater levels of skin clearance compared to placebo and to etanercept at the 12-week endpoint. Skin clearance was measured by standard primary endpoints for psoriasis studies: the Psoriasis Area and Severity Index (PASI) and the Static Physician Global Assessment (sPGA).
For patients treated with ixekizumab either every four weeks or every two weeks, between 78 to 90 percent of patients achieved at least a 75 percent reduction in PASI score (PASI 75) at 12 weeks. Additionally, 31 to 41 percent of these patients achieved PASI 100, or clear skin, at week 12. For comparison, between 5 to 7 percent of patients treated with etanercept in the UNCOVER-2 and 3 studies achieved PASI 100.
Statistically significant improvements in skin clearance measures for patients treated with ixekizumab were observed as early as the first week when compared to either placebo or etanercept, and continued through week 12. In the UNCOVER-1 study, high levels of response were maintained through 60 weeks of treatment.
Adverse events were comparable for patients receiving ixekizumab in the 12-week, randomized control portion across all three studies. The overall rates and severities of adverse events observed were comparable to those for etanercept in the two active comparator trials. The most frequently reported events (more than five percent across all three studies) were nasopharyngitis and injection site reaction. Most injection site reactions were mild, and most patients who experienced an injection site reaction continued treatment with ixekizumab.
"Moderate-to-severe plaque psoriasis can have a devastating life impact for patients," Ricks said. "Clear skin is their goal, but many patients are not able to achieve complete resolution using currently-available treatments."
Lilly plans to submit full data from the UNCOVER studies for disclosure at scientific meetings and in peer-reviewed journals in 2015. The company intends to submit ixekizumab to regulatory authorities in the first half of 2015.
"Ixekizumab was discovered and engineered to achieve high affinity and specificity to the IL-17A cytokine by Lilly Research Laboratories scientists, and is the most advanced asset in Lilly's pipeline of biotechnology-based medicines for the treatment of autoimmune diseases," said Tom Bumol, Ph.D., senior vice president of biotech discovery research, Lilly Research Laboratories, and president, Applied Molecular Evolution. "These data appear to confirm our hypothesis -- that IL-17A is a major driver of excess keratinocyte (skin cell) proliferation and activation in psoriasis. We're encouraged that this discovery by Lilly scientists could provide a new treatment option for patients with moderate-to-severe plaque psoriasis."
About the UNCOVER studies:
Patients enrolled in the UNCOVER studies had a confirmed diagnosis of chronic plaque psoriasis for at least six months prior to randomization. Additionally, at screening and at randomization they demonstrated at least 10 percent Body Surface Area (BSA) of psoriasis, an sPGA score of at least 3 and PASI score of at least 12. UNCOVER-1 compared the safety and efficacy of different dosing regimens of ixekizumab to placebo after 12 weeks and 60 weeks of treatment. UNCOVER-2 and 3 evaluated different dosing regimens of ixekizumab compared to either placebo or etanercept for 12 weeks.
About ixekizumab:
Ixekizumab is a monoclonal antibody with high affinity and specificity that binds to and neutralizes the pro-inflammatory cytokine interleukin-17A (IL-17A). In psoriasis, IL-17A plays a major role in driving excess keratinocyte (skin cell) proliferation and activation. Ixekizumab does not bind to cytokines IL-17B, IL-17C, IL-17D, IL-17E or IL-17F. Ixekizumab is administered via subcutaneous injection (under the skin). Ixekizumab is also in clinical development for the treatment of psoriatic arthritis.
"These data are important for people suffering from moderate-to-severe plaque psoriasis, as up to 41 percent of those treated with ixekizumab were able to achieve clear skin at week 12, with just one injection per dose. These results give us confidence that if approved, ixekizumab could make complete resolution of psoriasis possible for significantly more people," said David Ricks, Lilly senior vice president, and president, Lilly Bio-Medicines.
Posted by: Kat - Tue-19-08-2014, 14:58 PM
- Replies (1)
I have "medicine paranoia". No, I have not been officially diagnosed with that, but I really don't like taking different types of medicine at the same time. Not that anyone does. On a site, I saw where Meloxicam (I'm on a low dose, prescribed by my rheumatologist... I do not have PsA, it's for inflammation in my joints due to osteo arthritis) and a steroid MedPac (which I was just prescribed for a sprained wrist) can have a "moderate" interaction. I did tell the doctor that I was on Meloxicam and he said it was ok. I asked the light therapy nurse if it was ok for me to use the Fluocinolone Acetonide topical (which is a corticosteroid) if I take the steroid MedPac and she said it was fine. So, I asked the pharmacist (told you I was paranoid!) if it was ok to take the MedPac along with the 2 prescriptions I've mentioned plus the other meds I'm on (which I thought it was fine with those) and he said it was fine.
So, why am I hesitant to start the steroid MedPac? I don't see my GP until next month or I'd ask him as I feel he really pays attention to the overall picture. I've also laid off my Vit D supplement until after I meet with him since Acitretin and Light Therapy was added.
Posted by: Kat - Tue-19-08-2014, 14:28 PM
- Replies (4)
This is what the dermatologist diagnosed me with. I'm just learning about psoriasis so have not asked the doctor many questions, mostly just listened.
So, I've read this:
"Once the erythrodermic psoriasis flare passes, the psoriasis usually reverts to the way it looked before the flare".
Does that mean that it is a type of flare up as in I "had" erythrodermic psoriasis but could now have plague psoriasis or is it once diagnosed with erythrodermic, that's your diagnosis? I've had problems with infections (3 rounds of antibiotics but I think that was because it flared pretty bad right as I was getting diagnosed so things had got a bit out of control.) Right now, although still very red, it isn't that bright fiery red that it was.
Posted by: Fred - Tue-19-08-2014, 10:48 AM
- Replies (4)
This study suggests there is a high prevalence of Tinea Pedis (Athletes Foot) in people with psoriasis. Typically Tinea Pedis affects the feet, but may infect or spread to other areas of the body such as the groin and tends to spread to areas of skin that are kept hot and moist, such as with insulation, body heat, and sweat.
Quote:
There are discrepancies in the literature regarding the prevalence of tinea pedis in psoriasis. The aim of this investigation was to conduct a cross-sectional study of the prevalence of tinea pedis in psoriasis compared to atopic dermatitis patients and normal controls.
We enrolled 232 psoriatic patients, 190 atopic dermatitis patients and 202 normal controls, between the years 2010 and 2013. The prevalence of tinea pedis was 13.8% in psoriasis patients, not significantly different from that in atopic dermatitis patients 8.4% (P = 0.092)), but significantly higher than in normal controls 7.4% (P = 0.043). Both gender and age affected the prevalence of tinea pedis in psoriasis and normal controls, while only age affected the prevalence of tinea pedis in atopic dermatitis.
Regarding gender, there was higher prevalence of tinea pedis in men: 19.1% (P = 0.019) in psoriasis and 12.1% (P = 0.013) in normal controls. Age affected the prevalence of tinea pedis in normal controls (P < 0.001), psoriasis patients (P = 0.001) and atopic dermatitis patients (P = 0.001), with higher prevalence with increasing age. Trichophyton rubrum was the most common species in psoriasis (71.9%), atopic dermatitis (75.0%) and normal controls (73.3%).
Our study found a relatively high prevalence of tinea pedis among psoriasis patients.
I have an appt with one on weds. Curious to see what they will say about my skin. Was just wondering if anyone else here had tried this type of medical route.
Posted by: Kat - Sat-16-08-2014, 17:06 PM
- Replies (31)
Hello! I'm really happy to be here as this is all new to me.
A bit about myself... My name is Kathy (Kat for short) and I live in the U.S. in the state of Georgia. A bit over a year ago, my ears started to get red, itchy, scaly and I had no clue as to why so I just moisturized (which didn't help much.) After a couple of months, I had a visit with a doctor for a test and showed the nurse my ears and she recommended an over the counter cream... which as you can probably figure, didn't help either. A few months after that, I had a visit with my regular doctor and told him what was going on and also that I had a spot on my upper back and on my neck and he gave me a prescription cream..... which of course didn't help either. So on my follow up visit, 4 months later, he sent me to a dermatologist. By then it had started on my scalp and the doc took one look and said psoriasis. Initially, I was simply thinking, good, now maybe someone can fix it! So when he explained that psoriasis is "no cure" I thought... WHAT? I had heard of psoriasis, but thought it was such that you'd apply a cream and it would be gone. But, ok, so they have treatments, that won't be so bad, right? /sigh I had no understanding at all. Anyway, my first dermatologist visit was about 4 months ago and he prescribed a topical - Fluocinolone Acetonide Scalp Oil. Along with an antibiotic because I had a staph infection. So, I start using the messy oil. Over the past months, the psoriasis has came out on my face, neck, ears, back, elbows, knees and stomach. The oil helped somewhat with the itchiness but oh my, the scalp psoriasis is just horrible. I want to scratch myself to death and I leave a trail behind due to the scaling. So, back to the dermatologist I went and he put me on Acitretin (took the first one today as the pharmacy had to order it) and UVB light therapy (did the first session of 20 seconds on Friday, with three scheduled this next week and to continue at 3 per week until....they say everyone is different so no clue how many I'll need) so hopefully something helps.
So as you can see, I probably don't have a lot of helpful stuff to share on what has worked for me, but hopefully that changes with these treatments I've just started. I'm looking forward to reading through the forums and learning more as well as just chatting with people who understand.
Posted by: nishandj - Fri-15-08-2014, 04:36 AM
- Replies (11)
Hi,
I am a father to a 4 months old beautiful daughter. My mother has psoriasis and We are from Sri Lanka. There is no any organization directly related to psoriasis to talk to. Therefore I need your help and advises. Will my baby get psoriasis genetically from her grandmother? What tests we can have to know whether she is vulnerable to the psoriasis?
My mother has had it heavily at her younger age around 20 years old and now she is 57 with almost no visibility of psoriasis. But my daughter is showing no symptoms for now and I need to know whether it is possible to do certain tests. Thanks a lot in advance.
Posted by: Kellie71 - Sun-10-08-2014, 08:52 AM
- Replies (34)
Hello all,
A little ( not that little in truth ) introduction about myself. I have had Gout since my early 20's, which tied in nicely with developing Psoriasis, which was almost overnight in covering my scalp ( these were triggered I believe by the passing of both parents within a year of each other) was a good few years before I got that under control ( which is a slight understatement *wry smile*)
I was on the radar for Psoriatic Arthritis at least 6 years ago when my Rheumatologist mentioned it in a letter to my GP ( fortunately I have GP And specialist that send me a copy of all correspondence) No follow up... Until last year when it was followed up and diagnosed.
Diagnosed in September and treatment was Methotrexate, I did not take this until January this year.. this was just so I could research and get myself in the frame of mind to take this drug, highest dose was 17.5, and I was not going any higher, stopped in mid July to losing hair and frankly it not working. ( personally had a awful time on the drug) Because one has to fit a specific criteria for a biologic ( at my Rheumatologists in Kent) I have now been put on Sulphasalazine, which I have informed the Rheumatologist that this will be started at the end of this month.
My Introduction is now over and tea is much needed , Looking forward to contributing to the discussions on here . Kellie
"cl""cmy name is glenda and i have had psoriasis and psoriatic arthritis.I have had the psoriasis for about 15 yrs and didn't know i had it.Thought i had dandriff and dry skin on my ears.Then 9yrs ago my knees started swelling i was sent to a Rhemmy Dr he diagnosed me as having psoriatic arthritis.Tried so many medications none worked.So i was put on Remicade and had some adverse effects.So i am now waiting on a new drug Simponi Aura.The place where i got my infusion has not gotten back to my Dr.I am so miserable i am covered in plaques or scales.I went to see my Dermotologist and she suggested Stelara.I am going to have to get some help somewhere.I also have scalp psoriasis.No matter what i use nothing helps.
Posted by: Ruth91 - Sat-09-08-2014, 11:43 AM
- Replies (35)
Hey Guys, I'm new to this forum so hopefully I'm doing this the right way
I have had Psoriasis (covered head to toe in it) since I was a child, I tried EVERYTHING (creams, diets, UV light etc) which didn't work, and then I found Fumaderm
I have been on fumaderm for over 2 years now and I am down to 1 tablet and I am pretty much clear, except for the tiniest bit on my scalp. I can bare the side effects such as the flushing, but I am constantly tired which I believe is down to the Fumaderm. I will be seeing my dermatologist in September but before I speak to him I wanted to see if anyone has any experiences of coming off fumaderm and what happened.? I feel its time to come off it but I really don't know if its a good idea.
Any help would be very much appreciated, Ruth
Posted by: Fred - Fri-08-08-2014, 12:38 PM
- No Replies
Anakinra (Kineret) is an interleukin-1 (IL-1) receptor antagonist used to treat rheumatoid arthritis, here it was tested on two patients with with severe palmoplantar pustular psoriasis.
Quote:Background:
Palmoplantar pustular psoriasis is a clinical psoriasis variant characterised by a high impact on quality of life and poor response to biologics approved for plaque type psoriasis.The recombinant interleukin-1 (IL-1) receptor antagonist anakinra has been recently used for the treatment of isolated refractory cases of generalised pustular psoriasis with contrasted results.
Objectives:
To report the clinical response in two patients treated with anakinra as salvage therapy in two patients with severe palmoplantar pustular psoriasis refractory to currently available antipsoriatic systemic therapies.
Methods:
Anakinra was given subcutaneously at the daily dose of 100 mg, and clinical response was evaluated using the palmoplantar psoriasis area and severity index (PPPASI).
Results:
Only partial and transient responses were observed in both patients, who had to stop anakinra due to lack of efficacy and to side effects.
Conclusion:
Anakinra appears to provide only partial clinical improvement in refractory palmoplantar pustular psoriasis. Prospective clinical studies on larger populations are warranted to investigate more accurately both efficacy and safety of IL-1-inhibiting strategies in pustular psoriasis.
Posted by: Fred - Fri-08-08-2014, 12:31 PM
- No Replies
This study from The Journal of Dermatology suggests male predominance in psoriasis may occur in Japan.
Quote:
Psoriasis is thought to be a multifactorial disease triggered by both genetic and environmental factors. The HLA-C locus on chromosome 6p21.33 remains the strongest susceptibility candidate locus in psoriasis.
The strong association between psoriasis and the HLA-Cw6 allele has been well documented in various races. It is known that psoriatic patients with early onset are more likely to be familial and associated with HLA-Cw6. Familial occurrence of Japanese psoriasis is smaller than other populations. Furthermore, males are predominant over females in Japanese psoriasis.
We investigated the relation between HLA-C alleles and age of onset, and in each gender for Japanese psoriasis, and discuss male predominance in the incidence of psoriasis in Japan. Four hundred forty six unrelated Japanese patients with psoriasis vulgaris and 557 sex- and age-matched unrelated Japanese healthy controls were investigated by genotyping.
We confirmed the association between early-onset type of psoriasis with HLA-C*06:02 allele in Japanese. In addition, we detected the association between the late-onset type of psoriasis and the HLA-C*12:02 allele in Japanese. No significant differences in allele frequency were observed between females and males.
Our results suggest that there is no genetic factor effect on male predominance in Japanese. In contract, the effect of environmental risk factors on the onset of Japanese psoriatic patients is stronger in males than in females. As a result, male predominant in psoriasis may occur in Japan.
You have to register before you can post on our site.
Members Images
Join Psoriasis Club
Psoriasis Club is self funded, we don't rely on sponsorship or donations. We offer a safe
friendly forum and are proactive against spammers, trolls, and cyberbullying. Join us here!
No Advertising.
No Corprate Sponsors.
No Requests for Donations.
No Cyber-Bullying.
No Scams or Cures.
No Recruitment Posts.
No promotions or offers.
No Trolls.
No Spam.
Just a small bunch of friendly people with psoriasis sharing information and support.
Forum Statistics
» Members: 979 » Latest member: rphillips812003 » Forum threads: 7,045 » Forum posts: 255,299
There are currently 224 online users. »3 Member(s) | 220 Guest(s) "YOYO" The Psoriasis Club Bot Is On-line, Fred, scotty61, Turnedlight
Psoriasis Cure!
How many people have Psoriasis?
In 2012 there were approximately 36.5 million prevalent cases of psoriasis, and by 2022, GlobalData epidemiologists forecast that this figure will reach approximately 40.93 million.
The condition affects individuals of both sexes and all ethnicities and ages, although there is a higher prevalence of psoriasis in the colder, northern regions of the world.
The prevalence of psoriasis in the central region of Italy is 2.8 times greater than the prevalence in southern Italy.
Caucasians have a higher prevalence of psoriasis compared with African-Americans, but African-Americans in the US tend to suffer from a more severe form of the disease.